Stratigou Theodora, Muscogiuri Giovanna, Kotopouli Marianna, Antonakos Georgios, Christodoulatos Gerasimos S, Karampela Irene, Marinou Ioanna, Tsilingiris Dimitrios, Vallianou Natalia G, Vogiatzakis Evaggelos, Dalamaga Maria
Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Department of Endocrinology and First Department of Internal Medicine, Evangelismos General Hospital of Athens, Athens, Greece.
Panminerva Med. 2022 Dec;64(4):452-464. doi: 10.23736/S0031-0808.22.04701-2. Epub 2022 Jun 17.
Omentin-1, a newly discovered adipokine, is implicated in the modulation of the adipose phenotype, ameliorating systemic metabolism and exhibiting anti-atherogenic, anti-oxidative, cardioprotective, anti-inflammatory and insulin-sensitizing properties. Our goal was to explore circulating omentin-1 in subclinical hypothyroidism (SH) and determine its correlations with cardiometabolic risk factors.
In a large case-control and interventional longitudinal study, serum omentin-1, metabolic and lipid parameters, inflammatory biomarkers, classic adipocytokines and cardiovascular risk factors were assessed in 120 consecutive patients with SH and 120 healthy controls matched on age, gender and date of blood draw. Sixteen patients with SH were administered L-T4 and, after six months, circulating omentin-1 and other biomarkers were determined.
SH subjects presented significantly decreased circulating omentin-1 than control individuals (P<0.001). In all study participants, omentin-1 was negatively correlated with TSH, anti-thyroid antibodies, HOMA-IR, C-peptide, lipid and inflammatory biomarkers, adipokines and cardiovascular risk factors, including Framingham score and apolipoprotein B. Omentin-1 was positively associated with adiponectin and HDL-C. Circulating omentin-1 was independently associated with SH occurrence, above and beyond clinical and cardiometabolic factors (P=0.04). TSH was a negative independent predictor of serum omentin-1 levels (P<0.001). L-T4 treatment did not alter considerably the lower omentin-1 levels in treated SH patients (P=0.07).
Omentin-1 may be a useful non-invasive biomarker reflecting cardiometabolic risk as well as a promising therapeutic target. More mechanistic and larger prospective studies shedding light on the pathogenetic role of omentin-1 in SH are required to confirm these findings.
网膜素-1是一种新发现的脂肪因子，参与脂肪表型的调节，改善全身代谢，并具有抗动脉粥样硬化、抗氧化、心脏保护、抗炎和胰岛素增敏特性。我们的目标是探讨亚临床甲状腺功能减退症（SH）患者循环中的网膜素-1，并确定其与心脏代谢危险因素的相关性。
在一项大型病例对照和干预性纵向研究中，对120例连续的SH患者和120例年龄、性别及采血日期相匹配的健康对照者进行血清网膜素-1、代谢和脂质参数、炎症生物标志物、经典脂肪因子及心血管危险因素的评估。对16例SH患者给予左甲状腺素（L-T4）治疗，6个月后测定循环中的网膜素-1及其他生物标志物。
SH患者循环中的网膜素-1水平显著低于对照个体（P<0.001）。在所有研究参与者中，网膜素-1与促甲状腺激素（TSH）、抗甲状腺抗体、稳态模型评估的胰岛素抵抗指数（HOMA-IR）、C肽、脂质及炎症生物标志物、脂肪因子和心血管危险因素（包括弗雷明汉评分和载脂蛋白B）呈负相关。网膜素-1与脂联素和高密度脂蛋白胆固醇（HDL-C）呈正相关。循环中的网膜素-1与SH的发生独立相关，不受临床和心脏代谢因素影响（P=0.04）。TSH是血清网膜素-1水平的负性独立预测因子（P<0.001）。L-T4治疗未显著改变接受治疗的SH患者较低的网膜素-1水平（P=0.07）。
网膜素-1可能是反映心脏代谢风险的有用非侵入性生物标志物及有前景的治疗靶点。需要更多的机制研究和更大规模的前瞻性研究来阐明网膜素-1在SH发病机制中的作用，以证实这些发现。
